PGP and colorectal carcinoma: In CRC, DHTS can enhance the cytotoxicity of doxorubicin and irinotecan in P-gp overexpressing SW620 Ad300 colon cancer cells by reducing P-gp mRNA and protein levels, and by inhibiting P-gp ATPase activity [32].